Moderna Soars on Melanoma Breakthrough | Business and Finance News

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded19 Aug 2026

Publisherfeeds.acast.com ↗

Handlerec:20070414

Show notes

Moderna’s stock exploded 177% after stunning Phase Three melanoma trial results for its personalized neoantigen therapy, intismeran autogene—paired with Merck’s KEYTRUDA—showing real patient benefits. This breakthrough signals huge potential across other cancer trials, catapulting Moderna’s market value from $25B to $69B in one day. Investors are betting big on future growth, while the broader mRNA sector, including BioNTech and Pfizer, also surged—marking a pivotal moment for medical innovation and biotech markets. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/2199402202df556d

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.